TRVI TRVI

Trevi Therapeutics Stock Price

1.82
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
1.82
Volume 26,356
Bid Price 1.37
Ask Price 2.21
News -
Day High 1.93

Low
0.46

52 Week Range

High
4.6834

Day Low 1.82
Company Name Stock Ticker Symbol Market Type
Trevi Therapeutics Inc TRVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.82 17:00:00
Open Price Low Price High Price Close Price Prev Close
1.82 1.82 1.93 1.82 1.82
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
262 26,356 $ 1.86 $ 48,900 - 0.46 - 4.6834
Last Trade Time Type Quantity Stock Price Currency
14:42:35 27 $ 1.76 USD

Period:

Draw Mode:

Trevi Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 109.06M 59.92M 42.93M $ - $ - -1.50 -2.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 39.50k 1.70%

more financials information »

Trevi Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TRVI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.282.281.741.92102,085-0.46-20.18%
1 Month1.952.301.741.9665,171-0.13-6.67%
3 Months3.163.39661.432.08239,002-1.34-42.41%
6 Months2.404.68341.432.62840,483-0.58-24.17%
1 Year0.99594.68340.462.31765,0870.824182.75%
3 Years4.108.500.462.33333,131-2.28-55.61%
5 Years9.5010.620.462.45287,523-7.68-80.84%

Trevi Therapeutics Description

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.